We have unceasingly strived to realize our corporate philosophy of always making a contribution to human health.
Kyorin will continue to take on challenges and will evolve to become a company supporting healthy lifestyles through our business in the treatment and prevention of disease and the maintenance and promotion of good health.
- The purple border isCompany history
- The orange border isProduct history
1923年～
1923年
Toyo Shinyaku Sha, the predecessor of KYORIN Pharmaceutical Co., Ltd., was founded.
1931年
Kyorin Chemical Laboratory was established.
1940年
Kyorin Chemical Laboratory was renamed KYORIN Pharmaceutical Co., Ltd., and Kyorin Yakuhin Co., Ltd. was organized as an independent marketing division.
1947年
The Okaya Plant was started.
1950年～
1957年
The medical journal bulletin “Doctor Salon” was started.
1961年
Behyd, a diuretic and antihypertensive agent, was launched.
1962年
Kyorin Chemical Laboratory (later Technical Center of Development) was established.
1965年
The Head Office was completed in Kanda Surugadai.
KYORIN AP-2, an analgesic, was launched.
Deamelin-S, an oral hypoglycemic agent, was launched.
1967年
The Nogi Plant was opened.
1971年
Cholexamin, a lipid metabolism and peripheral circulation improving agent, was launched.
1974年
Hespander, a plasma substitute and extracorporeal circulation flow improver, was launched.
1977年
Central Research Laboratories were opened.
1980年～
1980年
Norfloxacin (NFLX), an antibacterial agent, was licensed to Merck & Co. (U.S.A.).
1981年
Mucodyne, a mucoregulant, was launched.
1984年
Baccidal (NFLX), a broadspectrum oral antibacterial agent, was launched.
1989年
Ketas, for bronchial asthma and cerebrovascular disorders, was launched.
Baccidal Eyedrops, a broadspectrum ophthalmic antibacterial agent, was launched.
1992年
KYORIN Pharmaceutical Co., Ltd. and Kyorin Yakuhin Co., Ltd. were merged, and the new KYORIN Pharmaceutical Co., Ltd. was founded.
1993年
Megalocin (FLRX), a long-acting new quinolone agent, was launched.
1995年
The Noshiro Plant was opened.
1996年
A joint venture, Nisshin KYORIN Pharmaceutical Co., Ltd., was established with Kyorin’s capital participation.
The Research Center (now the WATARASE Research Center) was founded.
Pentasa, a treatment for ulcerative colitis and Crohn’s disease, was launched.
Gatifloxacin (GFLX) was licensed to Bristol-Myers Squibb (U.S.A.).
1998年
Milton, an effervescent disinfectant business, was acquired from P&G.
1999年
Listed on the Tokyo Stock Exchange, Second Section.
2000年
Listed on the Tokyo Stock Exchange, First Section.
Gatifloxacin eyedrops was licensed to Allergan (U.S.A.).
2000年～
2001年
A subsidiary company, Kyorin USA, Inc. (U.S.A.), was established.
Kipres, the leukotriene receptor antagonist and bronchial asthma treatment medicine, was launched.
2002年
A subsidiary company, Kyorin Europe GmbH (Germany), was established.
Gatiflo (GFLX), a broad-spectrum, oral antibacterial agent, was launched.
2004年
ActivX Biosciences, Inc. (U.S.A.) became a wholly owned subsidiary.
2005年
The stock of Toyo Pharma Co., Ltd. (present KYORIN Rimedio Co., Ltd.) was acquired, making it into a subsidiary company.
2006年
The Nogi Plant was closed.
The Kyorin Group shifts to a holding company structure through a share exchange with KYORIN Co., Ltd.
2007年
Uritos Tablets 0.1 mg, an overactive bladder drug, was launched.
2008年
KYORIN Pharmaceutical merged with Nissin Kyorin Pharmaceutical.
2010年
KYORIN Co., Ltd. changed its name to KYORIN Holdings, Inc.
2010年～
2012年
Acquisition (conversion into subsidiary) of the Shiga Plant of MSD K.K. and established KYORIN Pharmaceutical Facilities Co., Ltd.
RUBYSTA, a multi-purpose disinfectant cleaner, was launched.
2013年
Head office moved to Ochanomizu sola city in Kanda Surugadai.
Flutiform, a combination drug for asthma treatment, was launched.
2015年
Establishment of the WATARASE Research Center of KYORIN Pharmaceutical Co., Ltd. through consolidation of the Drug Discovery Center (the former Central Research Laboratories) and the R&D Center (the former Research Center).
Eklira Genuair, a treatment for COPD, was launched.
FPR2 agonist program was licensed to Bristol-Myers Squibb Company (U.S.A.)
2016年
The Okaya Plant was closed
Montelukast tablets 10mg, 5mg「KM」, the leukotriene receptor antagonist and bronchial asthma treatment medicine, was launched.
DESALEX Tablets 5mg a treatment of allergic diseases drug was launched売
2017年
KYORIN Rimedio Co., Ltd.’s Takaoka Pharmaceutical Technology Innovation Center was established.
2018年
New manufacturing subsidiary, KYORIN Pharmaceutical Group Facilities Co., Ltd. (head office: Tokyo), commences operations.
Beova Tablets 50mg a treatment of OAB drug was launched.
2019年
GeneSoC®, a microchannel-based genetic measurement device, was launched.
2020年
KYORIN Pharmaceutical Group Facilities Co., Ltd. and KYORIN Medical Supply Co., Ltd. merge.
Lasvic Tablets 75mg an oral quinolone antibacterial agent was launched.
2020年～
2021年
Lasvic Intravenous Drip Infusion Kit 150mg an injectable new quinolone antibacterial agent was launched.
Zymso Intravesical Solution 50%, an interstitial cystitis treatmet was launched.
GeneSoC® mini was launched.
2022年
Lyfnua® Tablets 45mg Selective P2X3 receptor antagonist/Refractory chronic cough was launched.
ActivX Biosciences, Inc. was dissolved.
2023年
KYORIN Holdings, Inc. changed its trade name to KYORIN Pharmaceutical Co., Ltd. through absorption type merger of KYORIN Pharmaceutical Co., Ltd.